Gonewest,
instead of posting catchcries like portable loos, why not provide facts. Only fools cannot see Peter Cook and GSK are the greatest drag on BTA.
In a strong Northern seasonal flu the recent first half results speak for itself:
1)“Royalty income from sales of Relenza was $3,819 (2007: $16,483)”.DOWN 77%
2)“Collaboration income was $6,657 (2007: $9,560)” DOWN 30.4%
“Milestone payments of $NIL (2007: $3,419)” down 100% DESPITE R&D + Product development expenses increasing 17% from $10.584m to $12.361m. INCREASED EXPENSE = NO MILESTONE ACHIEVED = INCREASED EXECUTIVE REMUNERATIONS!!!
3) ”The underlying business booked a net loss of $12.8 million for the half versus net profit of $5.5 million previously”.
The Good news is one parasite had left the board.
LOL
- Forums
- ASX - By Stock
- BTA
- gsk is pushing relenza
gsk is pushing relenza, page-5
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online